NYSE:LHHealthcare
How Labcorp's FDA-Cleared Blood Test for Alzheimer’s Has Changed Its Investment Story (LH)
Labcorp recently announced the nationwide availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood-based in-vitro diagnostic test to support Alzheimer's disease diagnosis through early detection of amyloid plaques in adults showing cognitive decline.
This launch offers a less invasive and potentially more accessible alternative to current diagnostic methods, arriving as new clinical guidelines support wider use of blood-based biomarkers for Alzheimer’s...